La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Dextech Medical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Dextech Medical ha un patrimonio netto totale di SEK30.9M e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK32.0M e SEK1.1M.

Informazioni chiave

Rapporto debito/patrimonio netto

SEK 0

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 21.09m
Patrimonio netto	SEK 30.90m
Totale passività	SEK 1.13m
Totale attività	SEK 32.03m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Jan 10

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Sep 20

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

Jun 03

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

Feb 17

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Dec 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK21.6M ) di DEX superano le sue passività a breve termine ( SEK1.1M ).

Passività a lungo termine: DEX non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: DEX è esente da debiti.

Riduzione del debito: DEX non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: DEX ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: DEX ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a crescere a tassi storici del 1.4 % ogni anno

Dextech Medical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Recent updates

Dextech Medical AB Announces Continued Positive Results from Myeloma Study

Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023)

DexTech Medical Announces New Positive Results from the Myeloma Study

New major risk - Market cap size

Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Share price stability

Dextech Medical AB Announces Positive Results from the Myeloma Study

DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023)

Dextech Medical AB, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.31 loss in FY 2022)

New minor risk - Share price stability

Third quarter 2023 earnings released: kr0.079 loss per share (vs kr0.061 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.076 loss in 2Q 2022)

Dextech Medical AB to Report Fiscal Year 2024 Results on Aug 30, 2024

No independent directors

First quarter 2023 earnings released: kr0.044 loss per share (vs kr0.063 loss in 1Q 2022)

Dextech Medical AB Announces Upcoming Multiple Myeloma Study

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.41 loss in FY 2021)

Dextech Medical AB to Report Q1, 2023 Results on Oct 27, 2022

Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency

Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member

Third quarter 2022 earnings released: kr0.061 loss per share (vs kr0.10 loss in 3Q 2021)

No independent directors

DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020)

DexTech Medical AB Plans New Clinical Study on Multiple Myeloma

We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate

DexTech Medical AB Confirms Very Positive Results from Myeloma Studies

Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 3Q 2020)

What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?

New 90-day high: kr59.40

Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 2Q 2020)

DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma

New 90-day low: kr45.20

Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth

First quarter earnings released

Full year earnings released - kr0.52 loss per share

Full year earnings released - kr0.52 loss per share

New 90-day low - kr38.00

New 90-day low - kr42.00

New 90-day low - kr45.00

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane